Investors pushed shares of
higher on Wednesday on reports that two companies will use the electronics manufacturing outsourcer to build their products.
Jabil's stock recently tacked on $1.37, or 5.2% to $27.75.
, which develops tests to detect cardiovascular disease and cancer, said it had received permission from the U.S. Food and Drug Administration to market its second-generation Point of Care (POC) Skin Sterol Test, which assesses heart disease risk. Jabil will manufacture the product in its U.S. facilities.
In addition, according to media reports,
, based in Munich, has been negotiating with Jabil and
to outsource production of its handsets. BenQ has struggled to make a profit since taking over the business from
Jabil representatives were not immediately available for comment.
The company is scheduled to report its fourth-quarter earnings on Tuesday.